Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Stem Cells Mediated Mitochondria Transfer and Neuroprotection in Rodent Model of Ischemic Stroke
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
192
The aim of the study is to understand how intra-arterial (IA) mesenchymal Stem Cells (MSCs) can confer neuroprotection via mitochondria transfer following ischemic stroke in rodents. 
Stroke is a sudden cerebrovascular event contributing to death and disability in major population worldwide. Mitochondria plays a central role in the various mechanisms that are involved in stroke pathology. For post-ischemic neuroprotection, preserving the mitochondrial functionality is of utmost importance. IA MSCs is promising for stroke therapy with several pre-clinical and clinical studies establishing its safety and efficacy. Transfer of mitochondria from stem cells to damaged cells have been extensively studied in various pathologies and restoration of mitochondrial functionality has been reported following such transfer.
IA MSCs were infused in ovariectomized rats 6 hours post middle cerebral artery occlusion (MCAo) followed by 24 hours of reperfusion. Neurodeficits and motor functioning were evaluated and brains were harvested for infarct estimation, western blot analysis and immunohistochemistry. Brain mitochondria were isolated and analyzed for respiratory capacity, complex assays, membrane potential changes and mitochondrial reactive oxygen species (mitoROS) content. Mitochondria transfer was visualized through microscopy with a possible involvement of SIRT1 in the transfer.
Improvements in motor functioning and neurological deficits, with a reduction in infarct size were observed following MSCs infusion. Mitochondrial transfer was observed in the ischemic region. Improvements in mitochondrial respiratory capacity, complex activity and membrane potential were observed. Reduction in mitoROS also occurred. Increased expression of SIRT1, TFAM, MFN1, MFN2, PGC1a, OPA1 and RHOT1 were seen in the cortical brain regions. 
Mitochondrial transfer from MSCs towards ischemic neurons confer post stroke neuroprotection.
Authors/Disclosures
Deepaneeta Sarmah, M Pharm (National Institute of Pharmaceutical Â鶹´«Ã½Ó³»­ and Research-Ahmedabad (NIPER-A))
PRESENTER 		Miss Sarmah has nothing to disclose.
No disclosure on file
No disclosure on file
Dileep R. Yavagal, MD, FÂ鶹´«Ã½Ó³»­ (University of Miami Miller School of Medicine) Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vascular Dynamics. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. The institution of Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Medtronic. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus/Johnson & Johnson. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Poseydon. Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Athersys. Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gravity Medical Technology. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Poseydon. Dr. Yavagal has stock in Poseydon. Dr. Yavagal has stock in Galaxy Therapeutics. Dr. Yavagal has stock in Stentrode. Dr. Yavagal has stock in Gravity Medical. Dr. Yavagal has stock in Gravity Medical Technology. Dr. Yavagal has stock in Athersys. Dr. Yavagal has stock in Rapid Medical . Dr. Yavagal has received intellectual property interests from a discovery or technology relating to health care. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Expert with Royal Carribean Cruise Line. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Consultant with Carnival Cruise Line.
Pallab Bhattacharya, PhD (National Institute of Pharmaceutical Â鶹´«Ã½Ó³»­ and Research (NIPER),Ahmedabad.) Dr. Bhattacharya has nothing to disclose.